Artivion 2025 Q3 Earnings Profitability Resumes with 384% Net Income Surge

Artivion (AORT) delivered a strong Q3 2025 performance, surpassing revenue and profit expectations while raising full-year guidance. The company reported a 18.4% revenue increase to $113.39 million and returned to profitability with $0.14 EPS, reversing a $0.05 loss a year ago.

Revenue

Artivion’s total revenue surged 18.4% to $113.39 million in Q3 2025, driven by robust growth across core segments. Aortic stent grafts saw a 38% sales increase, fueled by the successful adoption of AMDS in the U.S. The On-X heart valve business grew 25%, supported by market share gains and clinical data. Surgical sealants and tissue processing contributed incremental gains, though at lower rates compared to key segments.

Earnings/Net Income

The company returned to profitability with net income of $6.50 million, a 384.2% improvement from a $2.29 million loss in 2024 Q3. EPS rose to $0.14, reflecting a 380% positive swing from a $0.05 loss. This turnaround underscores effective cost management and strong demand for core products.

Post-Earnings Price Action Review

The stock price declined 3.77% in the latest trading day and 1.10% weekly, but gained 9.47% month-to-date. A backtested strategy of purchasing shares on revenue-raise announcements over three years yielded $2.4 million in cumulative profit, with a 64.2% compound return. This historical performance aligns with the company’s positive earnings momentum.

CEO Commentary

CEO Pat Mackin highlighted 16% constant currency revenue growth, driven by 38% stent grafts growth and favorable AMDS trial data. Strategic priorities include advancing the ARTIZEN U.S. IDE trial for Arcevo and refinancing to extend debt maturity to 2031 with a new $150M delayed draw term loan. The company remains optimistic about outpacing revenue growth in EBITDA.

Guidance

Artivion raised 2025 guidance to constant currency revenue growth of 13–14% ($439–$445M) and adjusted EBITDA growth of 24–28% ($88–$91M). EBITDA is expected to grow twice as fast as revenue, supported by favorable currency trends and operational efficiencies.

Additional News

Artivion secured a $150 million delayed draw term loan to fund its ARTIZEN U.S. IDE trial for Arcevo and potential acquisitions, such as Endospan. The company also refinanced its credit agreement to extend debt maturity to 2031, reducing interest costs and improving liquidity. Additionally, the AMDS PERSEVERE and PROTECT trials presented at a European cardiothoracic surgery conference reinforced the product’s clinical efficacy.